Abstract:Children with Cystic Fibrosis (CF) are more likely to have intestinal dysbiosis due to recurrent antibiotic therapy and the conventional hypercaloric diet administered to them. This study aimed at evaluating the effect of isolated prebiotic components and probiotic strains, and their combinations as potential synbiotics, on the intestinal microbiota of CF children. A static in vitro colonic fermentation model was used by colonizing vials with faecal inoculum, a culture medium, and the substrates to be tested. Post treatment, aliquots were taken to determine ammonium, lactate, and short-chain fatty acids production and to profile the microbiota composition by 16s rRNA sequencing. At genus level, Escherichia-Shigella decreased (15.8%) with the treatment pectin + L. rhamnosus , followed by the beta-glucan + L. salivarius (15.5%). Inversely, the most increase in Bacteroides (44%) was obtained by the treatment with Pectin + L. reuteri . Lactate and acetic acid production was significantly increased with prebiotics and their combinations with L. rhamnosus and L. salivarius . In conclusion, the use of beta-glucan and pectin in combination with probiotic strains from the Lactobacillaceae family suggest potential to modulate dysbiosis and metabolic activity on CF colonic microbiota, encouraging further studies in animal studies or clinical settings to confirm the findings in vivo .

What problem does this paper attempt to address?

The paper attempts to address the issue of evaluating the effects of specific prebiotic components, probiotic strains, and their combinations (i.e., synbiotics) on the colonic microbiota of children with cystic fibrosis (CF). Specifically, the study aims to assess the potential regulatory effects of these components on the gut microbiota composition and metabolic activity of CF children using an in vitro static colonic fermentation model. ### Background Patients with cystic fibrosis (CF) are more prone to gut dysbiosis due to repeated antibiotic treatments and high-calorie diets. This imbalance in the microbiota is characterized by an increase in pathogenic bacteria and a decrease in microbial diversity, severely affecting the health status of the patients. Although there have been many studies on the lung microbiota of CF patients, research on the gut microbiota and its therapeutic strategies is relatively scarce. ### Research Objectives 1. **Evaluate single prebiotic components**: Including β-glucan, pectin, native starch, and resistant starch. 2. **Evaluate single probiotic strains**: Including Lactobacillus rhamnosus GG, Lactobacillus reuteri, and Lactobacillus salivarius. 3. **Evaluate combinations of prebiotics and probiotics** (synbiotics): A total of 12 different combinations. ### Methods - **Sample Source**: Fecal inocula obtained from 4 CF children. - **Experimental Design**: Using a static in vitro colonic fermentation model, fecal inocula, culture medium, and test substrates (prebiotics, probiotics, or synbiotics) were mixed in fermentation bottles. - **Analytical Methods**: Microbiota composition was analyzed by 16S rRNA gene sequencing, and the production of ammonia, lactate, and short-chain fatty acids (SCFAs) was measured. ### Main Findings - **Changes in Microbiota Composition**: - β-glucan and pectin, either alone or in combination with probiotics, significantly reduced the relative abundance of Firmicutes and increased the relative abundance of Bacteroidota. - Notably, the combination of pectin + L. reuteri increased the relative abundance of Bacteroidota by 44%. - **Changes in Metabolic Products**: - β-glucan and pectin significantly reduced ammonia concentration. - The probiotics L. rhamnosus and L. salivarius, when used in combination with prebiotics, significantly increased the production of lactate and acetate. ### Conclusion The study results suggest that the combination of β-glucan and pectin with probiotics from the Lactobacillaceae family may help regulate gut dysbiosis and metabolic activity in CF children. These findings provide a theoretical basis for further animal experiments or clinical studies.

In vitro screening of the impact of dietary prebiotic components, probiotic strains, and their symbiotic combinations on colonic microbiota in children with cystic fibrosis

Effect of Lactobacillaceae Probiotics on Colonic Microbiota and Metabolite Production in Cystic Fibrosis: A Comparative In Vitro Study

Impact of high-dose cholecalciferol (vitamin D3) and inulin prebiotic on intestinal and airway microbiota in adults with cystic fibrosis: A 2 × 2 randomized, placebo-controlled, double-blind pilot study

Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin D3) (Pre-D trial) in adults with cystic fibrosis

The Impact of Complementary Feeding on Fecal Microbiota in Exclusively Breast-Fed Infants with Cystic Fibrosis (A Descriptive Study)

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin D3) (Pre-D Trial) in adults with cystic fibrosis

Screening of probiotic strains to improve visceral hypersensitivity in irritable bowel syndrome by using in vitro and in vivo approaches

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin D ) (Pre-D Trial) in adults with cystic fibrosis

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor

Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants

In vitro intestinal simulation system on the carbon source utilization characteristics and mechanism of interspecific syntrophic effects of Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330

In vitro evaluation of the impact of human background microbiota on the response to Bifidobacterium strains and fructo-oligosaccharides

An in vitro medium for modeling gut dysbiosis associated with cystic fibrosis

Modeling the effects of prebiotic interventions on luminal and mucosa-associated gut microbiota without and with Clostridium difficile challenge in vitro

Effects of fructooligosaccharides and Saccharomyces boulardii on the compositional structure and metabolism of gut microbiota in students

Antioxidant Vitamins and Prebiotic FOS and XOS Differentially Shift Microbiota Composition and Function and Improve Intestinal Epithelial Barrier In Vitro

Intestinal Bacteroides modulates inflammation, systemic cytokines, and microbial ecology via propionate in a mouse model of cystic fibrosis

Modulation of the Altered Intestinal Microbiota by Use of Antibiotics with a Novel Synbiotic on Wistar Rats

Probiotic Characteristics of Lactiplantibacillus plantarum CECT 9435 and Its Survival and Competitive Properties Under Simulated Conditions of the Child Gut Microbiota

Gut Dysbiosis in Children with Cystic Fibrosis: Development, Features and the Role of Gut–Lung Axis on Disease Progression

In Vitro Screening for Probiotic Properties of Lactobacillus and Bifidobacterium Strains in Assays Relevant for Non-Alcoholic Fatty Liver Disease Prevention